Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b882006e755dfc56fcabfc5fb019f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ddcee08759aa6d16d32a4c19846697d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34f66a0e5da38bf6abf05a60fbca40ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_182cad34565986e59fcb21c48e8d3c5d |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50 |
filingDate |
2012-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93a254cdd27df66893d3e7192b8d7a1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02be58e4e406e8c4bf7633f1a6438c15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7b0efd65ee1e1371856c63288ef170d |
publicationDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8546378-B2 |
titleOfInvention |
5HT2C receptor modulator compositions and methods of use |
abstract |
The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015087634-A1 |
priorityDate |
2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |